

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 9/08, 9/14, 9/20, 9/48, 35/78	A1	(11) International Publication Number: WO 98/25588 (43) International Publication Date: 18 June 1998 (18.06.98)
(21) International Application Number: PCT/US97/21863 (22) International Filing Date: 26 November 1997 (26.11.97) (30) Priority Data: 08/766,618 13 December 1996 (13.12.96) US (71)(72) Applicant and Inventor: GORBACH, Sherwood, L. [US/US]; 31 Perry Lane, Weston, MA 02193 (US). (74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: ISOFLAVONOIDS FOR TREATMENT AND PREVENTION OF ALZHEIMER DEMENTIA AND REDUCED COGNITIVE FUNCTIONS (57) Abstract A method of treating or preventing, in a human patient, dementia of Alzheimer type, or age-related loss of cognitive function, said method comprising administering to said patient an isolated isoflavonoid selected from the group consisting of genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitin, and equol, in an amount sufficient to produce a transient isoflavonoid concentration in the bloodstream of said patient of at least 100 nanomoles/L.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ISOFLAVONOIDS FOR TREATMENT AND PREVENTION OF ALZHEIMER DEMENTIA AND REDUCED COGNITIVE FUNCTIONS

5

BACKGROUND OF THE INVENTION

The present invention relates to therapies for the prevention and treatment of dementia and reduced cognitive functions associated with advancing age.

10 It has long been recognized that dementia and diminished cognitive performance develop in persons over 65 years of age and these problems increase in frequency as the aging process advances. While these changes in cognitive behaviors are seen with the same frequency everywhere in the world, the types of dementing conditions differ in geographical areas. Thus, dementia of Alzheimer disease is more common than dementia of vascular

15 disease in North America and Europe, while the dominant pattern in Japan is vascular dementia which is nearly twice as common as Alzheimer dementia. Another factor that influences cognitive functions in older women is the use of estrogen replacement therapy (ERT). The risk of developing Alzheimer disease and related dementia is less in women who use ERT after the production of their own estrogen hormones declines at the time of

20 menopause. Cognitive function is improved in women who are given ERT for treatment of their dementia. Other drug treatments have been developed for Alzheimer dementia, but they are not fully effective and are associated with side effects. Safer and effective therapies for treating and preventing dementia and reduced cognitive function continue to be sought.

SUMMARY OF THE INVENTION

25

The invention features the use of isolated isoflavonoids, which are constituents of soy beans and other plants such as clover, to treat and prevent dementia of the Alzheimer type, as

-2-

well as other reduced cognitive functions associated with advancing age. Without being bound by any theory, it is believed that isoflavonoids have significant estrogenic activity, acting in the brain by enhancing neurotransmission and restoring synaptic density. It is believed that isoflavonoids are active in the brain at the same site as estrogen, exerting an estrogenic response. These compounds are safe and cause no significant side-effects.

Isoflavonoids which may be administered according to the invention include genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitin, and equol; these may be administered alone or in combination. The isolated isoflavonoid may be administered in any suitable form, e.g., in the form a plant extract rich in isoflavonoids or in the form of a purified or synthesized isoflavonoid. By "isolated" is meant the isoflavonoid is in a form which is more concentrated than the form in which it occurs naturally in plants. Treatment according to the invention is carried out using a therapeutic dietary product or a medicament form of one or more isolated isoflavonoid. The dietary product preferably includes a soy or plant extract enriched in isoflavonoids, provided in a palatable food carrier, e.g., a confectionary bar, biscuit, cereal or beverage. The medicament form preferably takes the form of a pill, tablet, capsule or powder, or a liquid or syrup formulation.

Other features and advantages of the invention will be apparent from the Detailed Description thereof, and from the claims.

DETAILED DESCRIPTION

Isoflavonoids are naturally occurring substances, found primarily in soy beans. These compounds can also be found in high concentrations in red clover and in lower amounts in many other types of plants. An isoflavonoid-containing fraction useful in the invention can be extracted from a soy or plant product. It is preferred that the isoflavonoids be extracted

-3-

and concentrated from soy bean or soy powder, but other plants such as clover can be used. Isoflavonoids are also available commercially in substantially pure form. The concentrated isoflavonoid is preferably included in a food carrier to form a dietary product. Any type of palatable carrier may be used, but as the isoflavonoid concentrate has a strong flavor, it is
5 preferred that the carrier include suitable flavorings to impart a different, more palatable flavor. The dietary product may be any type of food product, e.g., a confectionary bar, biscuit, cereal or beverage.

It is preferred that the dietary product contain at least 20 mg/serving total isoflavonoids. The isoflavonoid concentrate included in the dietary product preferably
10 includes a blend of isoflavonoids with genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitin, and equol; these may be administered alone or in combination. Preferably, a dietary product containing the preferred dosage of isoflavonoids is consumed at least once per day, more preferably 2 times per day for more severe symptoms.

15 The isoflavonoid also can be administered, preferably in similar dosages, in medicament form, e.g., mixed with a pharmaceutically acceptable carrier to form a pill, tablet, capsule or powder, or a liquid or syrup formulation.

When isoflavonoids are fed to healthy American adults, the absorption into the bloodstream is 10 to 20% of the amount consumed. This produces blood levels of
20 isoflavonoids 200 to 2000 times higher than the levels of the most active natural estrogen in women, estradiol. It is known that the estrogenic activity of isoflavonoids is about 1000 to 10,000 lower than that of estrogen contained in estrogen replacement therapy. These determinations indicate that consumption of isoflavonoids in dosages of 20 to 50 mg per day

-4-

provides blood levels with estrogenic activity in the range of that found with estrogen replacement therapy.

Other embodiments are within the claims.

We claim:

1. Use of an isolated isoflavonoid selected from the group consisting of genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitin, and equol, in an amount sufficient to
5 produce a transient isoflavonoid concentration in the bloodstream of a human patient of at least 100 nanomoles/L, in the preparation of a medicament for treating or preventing dementia of Alzheimer type, or age-related loss of cognitive function.
- 10 2. The use of claim 1 wherein medicament contains said isoflavonoid in an amount of at least 20 mg.
3. The use of claim 1 wherein there is administered to said patient at least one of genistein, daidzein, biochanin A, formononetin, O-
15 desmethylangolensin, glycitin, or equol.
4. The use of claim 1 wherein said medicament is in the form of a non-naturally occurring dietary product.
- 20 5. The use of claim 4 wherein said medicament contains at least 20 mg/serving of said isoflavonoid.

-6-

6. The use of claim 4 wherein said dietary product is a confectionary bar.

7. The use of claim 4 wherein said dietary product is a cereal.

5 8. The use of claim 4 wherein said dietary product is a biscuit.

9. The use of claim 4 wherein said dietary product is a beverage.

10. The use of claim 4 wherein said medicament is in the form of a pill.

10

11. The use of claim 4 wherein said medicament is in the form of a tablet.

12. The use of claim 4 wherein said medicament is in the form of a capsule.

15 13. The use of claim 4 wherein said medicament is in the form of a powder.

14. The use of claim 4 wherein said medicament is in the form of a liquid or syrup.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/21863

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/08, 9/14, 9/20, 9/48, 35/78.

US CL : 424/423, 195.1, 451, 464, 489, 422; 514/824, 879.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/423, 195.1, 451, 464, 489, 422; 514/824, 879.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,276,054 A (DIEZ et al.) 04 January 1994, entire document.	1-14
A, P	US 5,589,182 A (TASHIRO et al.) 31 December 1996, entire document.	1-14

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

17 FEBRUARY 1998

Date of mailing of the international search report

02 MAR 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

THEODORE J. CRIARES

Telephone No. (703) 308-1235